A 3-month treatment course of low-dose azithromycin for acute exacerbations of chronic obstructive pulmonary disorder appears to safely reduce treatment failure by preventing transfer to intensive care or readmission for respiratory causes, according to a posthoc analysis of the BACE* trial presented at the American Thoracic Society (ATS) 2019 International Conference.
Influenza vaccination effectively reduced the risk of influenza-related hospitalizations in patients with chronic obstructive pulmonary disease (COPD) compared with those who were not vaccinated, according to a study presented at ATS 2019.
Aside from improving exercise capacity and quality of life in patients with chronic obstructive pulmonary disease (COPD), pulmonary rehabilitation also yields reductions in anxiety and depression symptoms, according to the results of a systematic review and meta-analysis.
Long-acting beta2-agonist (LABA) plus long-acting muscarinic antagonist (LAMA) combinations compare with inhalers containing both LABA and corticosteroid (LABA-ICS) in terms of reducing chronic obstructive pulmonary disease (COPD) exacerbations, although the LAMA-LABA combination is more favourable as it is associated with fewer episodes of severe pneumonia, according to a study.
Vitamin D supplements can help reduce the rate of moderate-to-severe COPD* exacerbations in patients with inadequate vitamin D levels (<25 nmol/L) at baseline, but not in those with higher levels, according to a meta-analysis of randomized controlled trials (RCTs).
Digitalizing pulmonary rehabilitation using a smartphone app is feasible in the management of chronic obstructive pulmonary disease, with patients completing a 20-day core programme showing improvements in health-related quality of life, according to a study.
Combination therapy with inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) can be safely escalated to triple therapy in the management of patients with chronic obstructive pulmonary disease (COPD), a meta-analysis suggests. Specifically, adding a long-acting muscarinic receptor antagonist (LAMA) to the combination poses no major risk to increase cardiovascular serious adverse events.
New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.